| |
| Magyar Ortopéd Társaság |
|
| 24th Annual Meeting of the European Musculo-Skeletal Oncology Society |
 Rendezvény kezdete: 2011.05.18. | Rendezvény vége: 2011.05.20. |
| Munkahely neve: King Conventions bvba |
| Címe: 9000 Gent - Belgium - Korte Meer 16-18-20 |
| Tel: +32-9-235.22.95 |
| Fax: +32-9-233.85.97 |
| E-mail: EMSOS@Kingconventions.be |
| Helyszín: Belgium, 9000 Ghent, Onderbergen 1, Het Pand |
| A rendezvény Web oldala: http://www.emsos2011.be/ |
Deadline for abstract submission 20 Feruary 2011
Deadline for early bird registration 31 March 2011
|
|
|
 |
| |
| Magyar Endokrinológiai és Anyagcsere Társaság |
|
| XIV CAPRI CONFERENCE "Novel Mechanisms and clinical aspects of cardiovascular disorders |
| Rendezvény kezdete: 2011.04.15. | Rendezvény vége: 2011.04.17. |
| Szakterület(ek): Hipertónia, Kardiológia |
| Tudományos információ: Aristea International |
| Címe: Italy, 00198 Roma, Via Lima, 31 |
| Tel: +39 06 845431 |
| Fax: +39 06 84543700 |
| E-mail: roma@aristea.com |
| Szervező: Aristea International |
| Munkahely neve: Aristea |
| Címe: Italy, 00198 Roma, Via Lima, 31 |
| Tel: +39 06 845431 |
| Fax: +39 06 84543700 |
| E-mail: roma@aristea.com |
| Helyszín: www.capriconference.org, XIV CAPRI CONFERENCE "Novel Mechanisms and clinical aspects of cardiovascular disorders" |
The Capri Conference is an established and an international event where join together to develop and deal with the multiple and different discoveries that surround the Cardiovascular world.
This year our invited experts will discuss on various issues: from the management of Thromboembolism to the Atrial fibrillation, from new Antiplatelet Agents to Genetic aspects of Cardiomyopathies and to the latest guide line for the treatment of hypertension, heart and kidney.
The following are some of the Hot Topics:
• RAAS and metabolic syndrome
• Antialdosteronic therapy
• Lipids and cv events in the year 2011 – Residual risk
• New advances in the knowledge of renin
• Prevention/protection of MAU in hypertension
• BP targets in hypertension
• RAS and plaque stability
• RAS and vascular remodeling
• AT2 receptor agonists
• Prevention of CV disease in diabetes
• Prorenin/renin receptors
|
|
|
|
